Axial spondyloarthritis

This segment of Dr. Fakih’s interview featured a discussion on the implications of his team’s findings presented at ACR 2023.

The median central sensitization, frequency of neuropathic pain, and frequency of fibromyalgia diagnosis were higher in patients with axSpA when compared with controls.

Results of the SELECT-AXIS 2 study supported the efficacy and safety profile of upadacitinib in patients with active ankylosing spondylitis who had an inadequate response to biologic DMARD therapy.

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

There were no significant safety issues in the group of patients treated with secukinumab for more than 3 years.

Data from the CONSUL trial provide insight into the effects of TNF inhibitor monotherapy compared against combination therapy with NSAIDs for blunting radiographic spinal progression in adults with radiographic axial spondyloarthritis.

An analysis of more than 17,000 Veterans suggests early initiation of TNF inhibitor therapy in patients with ankylosing spondylitis was associated with an increased risk of incident cardiovascular disease and major adverse cardiovascular events.

Désirée van der Heijde, MD, PhD, explains the results of a recent trial evaluating the safety and efficacy of bimekizumab in patients with active ankylosing spondylitis.

Upadacitinib met the primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis and treatment-refractory active ankylosing spondylitis with inadequate response to biologic disease-modifying antirheumatic drugs.

Of 185 outpatients that completed the questionnaire, 146 patients (78.9%) were considered to have poor adherence to exercise therapy.

The European Alliance of Associations for Rheumatology (EULAR) recommends screening and early management of cardiovascular disease in patients with radiographic axial spondyloarthritis.

On April 29, AbbVie announced the US FDA had granted approval to upadacitinib 15 mg (RINVOQ) for treatment of active ankylosing spondylitis among adult patients who had inadequate response or intolerance to at least 1 TNF inhibitor.

“Understanding the impact of axSpA on pregnancy outcomes is a vital component of improving management of women with axSpA at every stage of their lives,” investigators stated.

Jessica Walsh, MD, explains the importance of understanding treatment satisfaction and decision-making in patients with axial spondyloarthritis based on patient-reported outcomes.

“Managing pain is an important treatment goal in patients with ankylosing spondylitis, however, pain is often underestimated by clinical disease activity scoring tools, and 20% to 30% of patients report pain despite treatment with TNFis,” investigators stated.